Local kinetics and dynamics of xenobiotics

Critical Reviews in Toxicology

Volumn 38, Issue 8, 2008, Pages 697-720

  Pelkonen, Olavi ^a   Kapitulnik, Jaime ^b   Gundert Remy, Ursula ^c   Boobis, Alan R ^d   Stockis, Armel ^e  

^a UNIVERSITY OF OULU   (Finland)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c Bundesinstitut fuer Risikobewertung   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UCB PHARMA   (Belgium)

Author keywords

Active site; BBB; Brain; Free concentration; Hepatocyte; Imaging; Lungs; Microdialysis; MS; PD; PK

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; XENOBIOTIC AGENT;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BLOOD LEVEL; BRAIN; BREATHING; CONCENTRATION (PARAMETERS); DIAGNOSTIC IMAGING; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; DYNAMICS; ENTEROHEPATIC CIRCULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KINETICS; LIVER; LIVER CELL; LUNG; LUNG ALVEOLUS CELL; LUNG PARENCHYMA; LUNG TOXICITY; MASS SPECTROMETRY; MICRODIALYSIS; MODEL; NONHUMAN; PASSIVE TRANSPORT; PHARMACODYNAMICS; PHYSIOLOGY; PLASMA PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIMULATION; SYSTEMIC CIRCULATION; TISSUE LEVEL;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION; XENOBIOTICS;

EID: 51749119926     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.1080/10408440802194931     Document Type: Review

References (120)

1. Anttila, S., Vainio, H., Hietanen, E., Camus, A.-M., Malaveille, C., Brun, G., Husgafvel-Pursiainen, K., Heikkilä, L., Karjalainen, A., and Bartsch, H. (1992). Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. Environ. Health Perspect. 98:179-182.
2. Anttila, S., Hukkanen, J., Hakkola, J., Stjernvall, T., Beaune, P., Edwards, R. J., Boobis, A. R., Pelkonen, O., and Raunio, H. (1997). Expression and localisation of CYP3A4 and CYP 3A5 in human lung. Am. J. Respir. Cell Mol. Biol. 16:242-247.
3. Austin, R.P., Barton, P., Cockroft, S.L., Wenlock, M.C., and Riley, R.J. (2002). The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 30:1497-1503.
4. Austin, R.P., Barton, P., Mohmed, S., and Riley, R.J. (2005). The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos. 33:419-425.
5. Baillie, T.A. (2006). Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19:889-893.
6. Baillie, T.A., Cayen, M.N., Fouda, H., Gerson, R.J., Green, J.D., Grossman, S.J., Klunk, L. J., LeBlanc, B., Perkins, D.G., and Shipley, L.A. (2002). Contemporary issues in toxicology. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182:188-196.
7. Barter, Z.E., Bayliss, M.K., Beaune, P.H., Boobis, A.R., Carlile, D.J., Edwards, R.J., Houston, J.B., Lake, B.G., Lipscomb, J.C., Pelkonen, O.R., Tucker, G.T., and Rostami-Hodjegan, A. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8:33-45.
8. Benet, L.Z., and Hoener, B.A. (2002). Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71:115-121.
9. Bernauer, U., Heinrich-Hirsch, B., Tönnies, M., Wolski, P., and Gundert-Remy, U. (2005). Cytochrome P450 2E1 (CYP2E1)-dependent chlorzoxazone hydroxylase activities in human lung microsomes. Naunyn-Schmiedebergs Arch. Pharmacol. Suppl. 1:371, R 93.
10. Bernauer, U., Heinrich-Hirsch, B., Tönnies, M., Wolski, P.M., and Gundert-Remy, U. (2006). Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol. Lett. 164:278-288.
11. Boffito, M., Back, D.J., Blaschke, T.F., Rowland, M., Bertz, R.J., Gerber, J.G., and Miller, V. (2003). Protein binding in anitretroviral therapies. AIDS Res. Hum. Retroviruses 19:825-835.
12. Bressler, J.P., Olivi, L., Cheong, J.H., Kim, Y., Maerten, A., and Bannon, D. (2007). Metal transporters in intestine and brain: Their involvement in metal-associated neurotoxicities. Hum. Exp. Toxicol. 26:221-229.
13. Brunner, M., and Langer, O. (2006). Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J. 8:E263-271.
14. Chandra, P., and Brouwer, K.L.R. (2004). The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm. Res. 21:719-735.
15. Chaurasia, C.S., Müller, M., Bashaw, E.D., Benfeldt, E., Bolinder, J., Bullock, R., Bungay, P.M., DeLange, E.C., Derendorf, H., Elmquist, W.F., Hammarlund-Udenaes, M., Joukhadar, C., Kellogg, D.L., Jr., Lunte, C.E., Nordstrom, C.H., Rollema, H., Sawchuk, R.J., Cheung, B.W., Shah, V.P., Stahle, L., Ungerstedt, U., Welty, D.F., and Yeo, H. (2007). AAPS-FDA Workshop White Paper: Microdialysis principles, application, and regulatory perspectives. J. Clin. Pharmacol. 47:589-603.
16. Christensen, H., Baker, M., Tucker, G.T., and Rostami-Hodjegan, A. (2006). Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J. Pharm. Sci. 95:2778-2787.
17. Coecke, S., Ahr, H., Blaauboer, B.J., Bremer, S., Casati, S., Castell, J., Combes, R., Corvi, R., Crespi, C.L., Cunningham, M.L., Elaut, G., Eletti, B., Freidig, A., Gennari, A., Ghersi-Egea, J.F., Guillouzo, A., Hartung, T., Hoet, P., Ingelman-Sundberg, M., Munn, S., Janssens, W., Ladstetter, B., Leahy, D., Long, A., Meneguz, A., Monshouwer, M., Morath, S., Nagelkerke, F., Pelkonen, O., Ponti, J., Prieto, P., Richert, L., Sabbioni, E., Schaack, B., Steiling, W., Testai, E., Vericat, J.A., and Worth, A. (2006). Metabolism: A bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM Workshop 54. Altern. Lab. Anim. 34:49-84.
18. Colombo, S., Buclin, T., Decosterd, L.A., Telenti, A., Furrer, H., Lee, B.L., Biollaz, J., and Eap, C.B. (2006). Orosomucoid (alpha(1)-acid glycoprotein) plasma concentration and genetic variants: effects of human immunodeficieny virus protease inhibitor clearance and cellular accumulation. Clin. Pharmacol. Ther. 80:307-318.
19. Crawford, E.L., Weaver, D.A., DeMuth, J.P., Jackson, C.M., Khuder, S.A., Frampton, M.W., Utell, M.J., Thilly, W.G., and Willey, J.C. (1998). Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. Carcinogenesis 19:1867-1871.
20. Csajka, C., and Verotta, D. (2006). Pharmacokinetic-pharmacodynamic modeling: History and perspectives. J. Pharmacokinet. Pharmacodyn. 33:227-279.
21. Czerwinski, M., McLemore, T.L., Gelboin, H.V., and Gonzalez, F.J. (1994). Quantitation of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res. 54:1085-1091.
22. Dallas, S., Miller, D.S., and Bendayan, R. (2006). Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacol. Rev. 58:140-161.
23. de Boer, A.G., van der Sandt, I.C.J., and Gaillard, P.J. (2003). The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 43:629-656.
24. Deeken, J.F., and Löscher, W. (2007). The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin. Cancer Res. 13:1663-1674.
25. Drexler, D.M., Garrett, T.J., Cantone, J.L., Diters, R.W., Mitroka, J.G., Prieto Conaway, M. C., Adams, S.P., Yost, R.A., and Sanders, M. (2007). Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J. Pharmacol. Toxicol. Methods 55:279-288.
26. Edginton, A.N., Schmitt, W., Voith, B., and Willmann, S. (2006a). A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 45:683-704.
27. Edginton, A.N., Schmitt, W., and Willmann, S. (2006b). Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45:1013-1034.
28. Faber, K. N., Müller, M., and Jansen, P. L. M. (2003). Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 55:107-124.
29. Foth, H. (1995). Role of the lung in accumulation and metabolism of xenobiotic compounds - Implications for chemically induced toxicity. Crit. Rev. Toxicol. 25:165-205.
30. Friberg, L.E., Henningsson, A., and Maas, H. (2002). Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20:4713-4721.
31. Friden, M., Gupta, A., Antonsson, M., Bredberg, U., and Hammarlund-Udenaes, M. (2007). In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719.
32. Gerk, P.M., and Vore, M. (2005). The ileocyte basolateral organic solute transporter (OSTα-OSTβ) complex: Finding the missing link in enterohepatic circulation. Mol. Interv. 5:8-10.
33. Ghibellini, G., Vasist, L.S., Leslie, E.M., Heizer, W.D., Kowalsky, R.J., Calvo, B.F., and Brouwer, K.L. (2007). In vitro - in vivo correlation of hepatobiliary drug clearance in humans. Clin. Pharmacol. Ther. 81:406-413.
34. Gillette, J.R. (1963). Drug metabolism by enzyme mechanisms. Prog. Drug Res. 6:55-57.
35. Gülden, M., Mörchel, S, Tahan S, Seibert H (2002). Impact of protein binding on the availability and cytotoxic potency of organochlorine pesticides and chlorphenols in vitro. Toxicology 175: 201-213.
36. Hammarlund-Udenaes, M. (2000). The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv. Drug Deliv. Rev. 45:283-294.
37. Heringa, M.B., and Hermens, J.L.M. (2003). Measurement of free concentrations using negligible depletion-solid phase microextraction (ND-SPME). Trends Anal. Chem. 22:575-587.
38. Heringa, M.B., Schreuers, R.H.M.M., Busser, F., van der Saag, P.T., van der Burg, B., and Hermens, J.L.M. (2004). Toward more useful in vitro toxicity data with measured free concentrations. Environ. Sci. Technol. 38:6263-6270.
39. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.L., and Karlsson, J. (2007). Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35:1333-1340.
40. Howgate, E.M., Rowland-Yeo, K., Proctor, N.J., Tucker, G.F., and Rostami-Hodjegan, A. (2006). Prediction of in vivo clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36:473-497.
41. Hukkanen, J., Pelkonen, O., Hakkola, J., and Raunio, H. (2002). Expression and regulation of xenobiotic metabolizing Cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 32:391-411.
42. Ingelman-Sundberg, M. (2001). Genetic variability in susceptibility and response to toxicants. Toxicol. Lett. 120:259-268.
43. Inoue, S., Howgate, E.M., Rowland-Yeo, K., Shimada, T., Yamazaki, H., Tucker, G.T., and Rostami-Hodjegan, A. (2006). Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 36:499-513.
44. Johnson, T.N., Rostami-Hodjegan, A., and Tucker, G.T. (2006). Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45:931-956.
45. Joo, F. (1996). Endothelial cells of the brain and other organ systems: Some similarities and differences. Prog. Neurobiol. 48:255-273.
46. Joss, J.D., and LeBlond, R.F. (2000). Potentiation of warfarin anticoagulation associated with topical methyl salicylate. Ann. Pharmacother. 34:729-733.
47. Joukhadar, C., and Muller, M. (2005). Microdialysis: Current applications in clinical pharmacokinetic studies and its potential role in the future. Clin. Pharmacokinet. 44:895-913.
48. Kanamitsu, S., Ito, K., and Sugiyama, Y. (2000). Quantitative prediction of in vivo drug - drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 17:336-343.
49. Kaplowitz, N (2005). Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4:489-499.
50. Kivistö, K. T., Griese, E.-U., Fritz, P., Linder, A., Hakkola, J., Raunio, H., Beaune, P., and Kroemer, H.K. (1996). Expression of cytochrome P4503A enzymes in human lung: A combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumors. Naunyn-Schmiedeberg Arch. Pharmacol. 353:207-212.
51. Kivistö, K.T., Griese, E.-U., Stuven, T., Fritz, P., Friedel, G., Kroemer, H.K., and Zanger, U.M. (1997). Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 7:295-302.
52. Kivistö, K.T., and Niemi, M. (2007). Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24:239-247.
53. Koo, V., Hamilton, P.W., and Williamson, K. (2006). Non-invasive in vivo imaging in small animal research. Cell Oncol. 28:127-139.
54. Kostiainen, R., Kotiaho, T., Kuuranne, T., and Auriola, S. (2003). Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J. Mass Spectrom. 38:357-372.
55. Lammertsma, A.A. (2001). PET/SPECT: Functional imaging beyond flow. Vision Res. 41:1277-1281.
56. Lammertsma, A.A. (2002). Radioligand studies: Imaging and quantitative analysis. Eur. Neuropsychopharmacol. 12:513-516.
57. Langer, O., and Muller, M. (2004). Methods to assess tissue-specific distribution and metabolism of drugs. Curr. Drug Metab. 5:463-481.
58. Lee, C.M., and Farde, L. (2006). Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol. Sci. 27:310-316.
59. Lee, W., and Kim, R.B. (2004). Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol. 44:137-166.
60. Lennernäs, H. (2007). Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: Experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metab. 8:645-657.
61. Lin, T.H., and Lin, J.H. (1990). Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. J. Pharmacol. Exp. Ther. 253:45-50.
62. Lindberger, M., Tomson, T., and Lars, S. (2002). Microdialysis sampling of carbamazepine, phenytoin and phenobarbital in subcutaneous extracellular fluid and subdural cerebrospinal fluid in humans: An in vitro and in vivo study of adsorption to the sampling device. Pharmacol. Toxicol. 91:158-165.
63. Lipscomb, J.C., Teuschler, L.K., Swartout, J., Popken, D., Cox, T., and Kedderis, G.L. (2003). The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal. 23:1221-1238.
64. Lipscomb, J.C. (2004). Evaluating the relationship between variance in enzyme expression and toxicant concentration in health risk assessment. Hum. Ecol. Risk Assess. 10:39-55.
65. Macé, K., Bowman, E.D., Vautravers, P., Shields, P.G., Harris, C.C., and Pfeifer, A.M.A. (1998). Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissue. Eur. J Cancer 34:914-920.
66. Marshall, S., Macintyre, F., James, I., Krams, M., and Jonsson, N.E. (2006). Role of mechanistically-based pharmacokinetic/ pharmacodynamic models in drug development - A case study of a therapeutic protein. Clin. Pharmacokinet. 45:177-197.
67. McGregor, D., Bolt, H., Cogliano, V., and Richter-Reichhelm, H.-B. (2006). Formaldehyde and glutaraldehyde and nasal cytotoxicity: Case study within the context of the 2006 IPCS Human Framework for the Analysis of a Cancer Mode of Action for Humans. Crit. Rev. Toxicol. 36:821-835.
68. McLure, J.A., Miners, J.O., and Birkett, D.J. (2000). Nonspecific binding of drugs to human liver microsomes. Br. J. Clin. Pharmacol. 49:453-461.
69. Meineke, I., Feltkamp, H., Högemann, A., and Gundert-Remy, U. (1997) Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexitil in patients with mild to moderate essential hypertension - A population analysis. Eur. J. Clin. Pharmacol. 53:221-228.
70. Meyer, R.P., Gehlhaus, M., Knoth, R., and Volk, B. (2007). Expression and function of cytochrome p450 in brain drug metabolism. Curr. Drug Metab. 8:297-306.
71. Mizuno, N., Niwa, T., Yotsumoto, Y., and Sugiyama, Y. (2003). Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55:425-461.
72. Muller, M. (2002). Science, medicine, and the future: Microdialysis. Br. Med. J. 324:588-591.
73. Nigsch, F., Klaffke, W., and Miret, S. (2007). In vitro models for processes involved in intestinal absorption. Expert Opin. Drug Metab. Toxicol. 3:545-556.
74. Noé, J., Portmann, R., Brun, M.E., and Funk, C. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 35:1308-1314.
75. Ohtsuki, S., and Terasaki, T. (2007). Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; Importance for CNS drug discovery and development. Pharm. Res. 24:1745-1758.
76. Pacifici, G.M., and Pelkonen, O., eds. (2001). Variation of drug metabolism in humans. London: Taylor & Francis.
77. Palm, K., Luthman, K., Ungell, A.L., Strandlund, G., Beigi, F., Lundahl, P., and Artursson, P. (1998). Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors. J. Med. Chem. 41:5382-5392.
78. Pardridge, W.M. (2007). Blood-brain barrier delivery. Drug Discov. Today 12:54-61.
79. Park, B.K., Kitteringham, N.R., Maggs, J.L., Pirmohamed, M., and Williams, D.P. (2005). The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45:177-202.
80. Park, K.B., Dalton-Brown, E., Hirst, C., and Williams, D.P. (2006). Selection of new chemical entities with decreased potential for adverse drug reactions. Eur. J. Pharmacol. 549:1-8.
81. Pelkonen, O., and Turpeinen, M. (2007). In vitro-in vivo extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 37:1066-1089.
82. Perriere, N., Yousif, S., Cazaubon, S., Chaverot, N., Bourasset, F., Cisternino, S., Decleves, X., Hori, S., Terasaki, T., Deli, M., Scherrmann, J.M., Temsamani, J., Roux, F., and Couraud, P.O. (2007). A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res. 1150:1-13.
83. Piipari, R., Savela, K., Nurminen, T., Hukkanen, J., Raunio, H., Hakkola, J., Mäntylä, T., Beaune, P., Edwards, R.J., Boobis, A.R., and Anttila, S. (2000). Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon - DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int. J. Cancer 86:610-616.
84. Rendic, S., and Di Carlo, F.J. (1997). Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29:413-580.
85. Roberts, M.S., Magnusson, B.M., Burczynski, F.J., and Weiss, M. (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41:751-790.
86. Rostami-Hodjegan, A., and Tucker, G.T. (2004). 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov. Today Technol. 1:441-448
87. Rostami-Hodjegan, A., and Tucker, G.T. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6:140-148.
88. Runge, D.M., Stock, T.W., Lehmann, T., Taege, C., Bernauer, U., Stolz, D., Hofmann, S., and Foth, H. (2001). Activation of cytochrome P450 2E1 by ethanol in normal human bronchial epithelial cells. Arch. Toxicol. 75:335-345.
89. Rylander, T., Neve, E.P.A., Ingelman-Sundberg, M., and Oscarson, M. (2001). Identification and tissue distrubution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem. Biophys. Res. Commun. 281:529-534.
90. Sasongko, L., Link, J.M., Muzi, M., Mankoff, D.A., Yang, X., Collier, A.C., Shoner, S.C., and Unadkat, J.D. (2005). Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther. 77:503-514.
91. Seibert, H., Mörchel, S., and Gülden, M (2002). Factors influencing nominal concentrations of chemical compounds in vitro: Medium protein concentration. Toxicol. In Vitro 16:289-297.
92. Shiran, M.R., Proctor, N.J., Howgate, E.M., Rowland-Yeo, K., Tucker, G.T., and Rostami-Hodjegan, A. (2006). Prediction of metabolic drug clearance in humans: In vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 36:567-580.
93. Shitara, Y., Horie, T., and Sugiyama, Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27:425-446.
94. Shitara, Y., Sato, H., and Sugiyama, Y. (2005). Evaluation of drug - drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45:689-723.
95. Shitara, Y., and Sugiyama, Y. (2006). Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug - drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112:71-105.
96. Shou, M., Lu, W., Kari, P.H., Xiang, C., Liang, Y., Lu, P., Cui, D., Emary, W.B., Michel, K. B., Adelsberger, J.K., Brunner, J.E., and Rodrigues, A.D. (2005). Population pharmacokinetic modeling for enterohepatic recirculation in rhesus monkey. Eur. J. Pharm. Sci. 26:151-161.
97. Solon, E.G., Balani, S.K., and Lee, F.W. (2002). Whole-body autoradiography in drug discovery. Curr. Drug Metab. 3:451-462.
98. Spareboom, A., Nooter, K., Loos, W.J., and Verweij, J. (2001). The (irr)relevance of plasma protein bining of anticancer drugs. Neth. J. Med. 59:196-207.
99. Stumpf, W.E. (2007). Memo to the FDA and ICH: Appeal for in vivo drug target identification and target pharmacokinetics. Recommendations for improved procedures and requirements.Drug Discov. Today 12:594-598.
100. Syvänen, S., Blomquist, G., Sprycha, M., Urban Höglund, A., Roman, M., Eriksson, O., Hammarlund-Udenaes, M., Långström, B., and Bergström, M. (2006). Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. NeuroImage 32:1134-1141.
101. Syvänen, S., Xie, R., Sahin, S., and Hammarlund-Udenaes, M. (2006). Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm. Res. 23:705-717.
102. Tanaka, H., and Mizojiri, K.J. (1999). Drug - protein binding and blood-brain barrier permeability Pharmacol. Exp. Ther. 288:912-918.
103. Trauner, M., and Boyer, J.L. (2003). Bile salt transporters: Molecular characterization, function, and regulation. Physiol. Rev. 83:633-671.
104. Treiber, A., Schneiter, R., Häusler, S., and Stieger, B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35:1400-1407.
105. Tucker, G.T., Houston, J.B., and Huang, S.M. (2001). Optimising drug development: Strategies to assess drug metabolism/transporter interaction potential - Towards a consensus. European Federation of Pharmaceutical Sciences conference report. Eur. J. Pharm. Sci. 13:417-428.
106. Upton, R.N. (2007). Cerebral uptake of drugs in humans. Clin. Exp. Pharmacol. Physiol. 34:695-701.
107. Van, L.M., Heydari, A., Yang, J., Hargreaves, J., Rowland-Yeo, K., Lennard, M.S., Tucker, G. F., and Rostami-Hodjegan, A. (2006). The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). J. Psychopharmacol. 20:834-841.
108. Willmann, S., Edginton, A.N., and Dressman, J.B. (2007). Development and validation of a physiology-based model for the prediction of absorption in monkeys. Pharm. Res. 24:1275-1282.
109. Willmann, S., Höhn, K., Edginton, A., Sevestre, M., Solodenko, J., Weiss, W., Lippert, J., and Schmitt, W. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34:401-431.
110. Willmann, S., Lippert, J., Sevestre, M., Solodenko, J., Fois, F., and Schmitt, W. (2003). PK-SIM(r): A physiologically based pharmacokinetic 'whole-body' model. Biosilico 1:121-124.
111. Willmann, S., Schmitt, W, Keldenich, J., and Dressman, J.B. (2003). A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res. 20:1766-171.
112. Willmann, S., Schmitt, W., Keldenich, J., Lippert, J., and Dressman, J.B. (2004). A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47:4022-4031.
113. Workman, P., Aboagye, E.O., Chung, Y.L., Griffiths, J.R., Hart, R., Leach, M.O., Maxwell, R. J., McSheehy, P.M., Price, P.M., and Zweit, J. (2006). Cancer Research UK Pharmacodynamic/ Pharmacokinetic Technologies Advisory Committee. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. JNCI 98:580-598.
114. Willey, J.C., Coy, E., Brolly, C., Utell, M.J., Frampton, M.W., Hammersley, J., Thilly, W.G., Olson, D., and Cairns, K. (1996). Xenobiotic metabolism gene expression in human bronchial epithelial and alveolar macrophage cells. Am. J. Respir. Cell Mol. Biol. 14:262-271.
115. Wu, S., Moomaw, C.R., Tomer, K.B., Falck, J.R., and Zeldin, D.C. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxigenase highly expressed in heart. J. Biol. Chem. 271:3460-3464.
116. Yamano, K., Yamamoto, K., Kotaki, H., Takedomi, S., Matsuo, H., Sawada, Y., and Iga, T. (1999). Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats. Drug Metab. Dispos. 27:1225-1231.
117. Yamano, K., Yamamoto, K., Kotaki, H., Takedomi, S., Matsuo, H., Sawada, Y., and Iga, T. (2000). Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: Implication of concentrative uptake of inhibitors into liver. J. Pharmacol. Exp. Ther. 292:1118-1126.
118. Yokel, R.A. (2006). Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J. Alzheimers Dis. 10:223-253.
119. Zhang, N., Fountain, S.T., Bi, H., and Rossi, D.T. (2000). Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC/MS. Anal. Chem 72:800-806.
120. Zhang, Y., Han, H.Y., Elmquist, W.F., and Millen, D.W. (2000). Expression of various multidrug resistance-associated protein MRP homologues in brain microvessel endothelial cells. Brain Res. 876:148-153.